Drug intelligence / Profile preview

levocarnitine + methylphenidate

Development stage
Unknown
Lead developer
Sigma Tau Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Intravenous, Transdermal
01

Overview

Levocarnitine + methylphenidate is a combination of two agents, each with distinct mechanisms and indications. Levocarnitine (L-carnitine) is a naturally occurring amino acid derivative involved in the transport of long-chain fatty acids into mitochondria for energy production, primarily used to treat carnitine deficiency[4][7]. Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine, enhancing neurotransmission in the brain; it is widely used for attention deficit hyperactivity disorder (ADHD) and narcolepsy[6]. The combination has been studied as an adjunctive therapy for ADHD, but clinical trials have not demonstrated significant additional benefit over methylphenidate alone[1][2][5][8]. Both drugs are available as generics.

Other names
methylphenidate and carnitinemethylphenidate plus carnitine
02

Targets

NET (Norepinephrine Transporter)SLC22A5 (Organic cation/carnitine transporter 2)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on levocarnitine + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levocarnitine + methylphenidate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call